Traders should expect high volatility around the 8:00 a.m. ET conference call where management details the Type C meeting strategy. The primary-miss + salvageable-subgroup mix often drives a sharp initial selloff followed by recovery if the regulatory path is credible.
Price Chart
Executive Summary
Tenax Therapeutics announced that its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in PH-HFpEF missed the primary endpoint of improvement in 6-minute walk distance (p=0.63) and a key secondary endpoint. However, prespecified subgroup analyses showed a significant 26.3-meter improvement in patients with lower baseline walk distance, a 49% NT-proBNP reduction (p<0.0001), and a 3.5 mmHg RVSP reduction (p=0.0045). The company plans to request a Type C meeting with the FDA to discuss an enriched development path, citing prior FDA agreement that a single Phase 3 trial with p≤0.01 could support an NDA.
Key Facts
- LEVEL trial missed primary endpoint: 6MWD LS mean difference +3.5 meters (p=0.63) vs placebo.
- KCCQ-TSS secondary endpoint also missed: LS mean difference +0.1 points.
- Prespecified subgroup with baseline 6MWD <333m showed +26.3 meter improvement (p=0.0112, nominal).
- NT-proBNP reduced 49% vs placebo (p<0.0001, nominal) in overall population.
- RVSP reduced 3.5 mmHg vs placebo (p=0.0045, nominal) in overall population.
- 241 patients randomized; drug well-tolerated with balanced serious adverse events (10.8% vs 10.7%).
- Company to request Type C meeting with FDA to discuss enriched registrational path.
- FDA previously agreed a single Phase 3 trial with p≤0.01 could support NDA for TNX-103 in PH-HFpEF.
- Full results to be presented at ESC Congress 2026 (Aug 28-31).
Financial Impact
TENX market cap of $503M faces binary outcome: primary miss is negative, but strong subgroup and biomarker signals coupled with FDA flexibility on a single pivotal trial create potential for regulatory salvage.
Risk Factors
- FDA may reject enrichment approach requiring a second Phase 3 trial, extending timeline and cash burn.
- Nominal p-values in subgroup analyses are not adjusted for multiplicity; FDA may deem insufficient for registration.
- Adverse event imbalance (86.7% vs 71.9%) could raise safety concerns despite balanced SAEs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341675 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.64 (+20.59%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.64 (+2.50%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.64 (−10.38%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.64 (−12.30%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.64 (−13.68%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.64 (−23.00%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.64 (−10.87%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.64 (−88.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers